Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation and Depletion (2022 - 2024)

Orchestra BioMed Holdings (OBIO) has disclosed Depreciation and Depletion for 3 consecutive years, with $84000.0 as the latest value for Q4 2024.

  • Quarterly Depreciation and Depletion rose 16.67% to $84000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $308000.0 through Dec 2024, up 7.69% year-over-year, with the annual reading at $327000.0 for FY2025, 6.17% up from the prior year.
  • Depreciation and Depletion for Q4 2024 was $84000.0 at Orchestra BioMed Holdings, up from $76000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $84000.0 in Q4 2024, with the low at $48000.0 in Q1 2022.
  • Average Depreciation and Depletion over 3 years is $67916.7, with a median of $71500.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion soared 47.92% in 2023, then rose 2.78% in 2024.
  • Over 3 years, Depreciation and Depletion stood at $70000.0 in 2022, then increased by 2.86% to $72000.0 in 2023, then grew by 16.67% to $84000.0 in 2024.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $84000.0, $76000.0, and $74000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.